Literature DB >> 20632100

Antiglycan antibodies in Greek patients with inflammatory bowel disease.

Ioannis E Koutroubakis1, Dimitrios Drygiannakis, Alexandra Tsirogianni, Pantelis Oustamanolakis, Konstantinos Karmiris, Konstantinos Papamichael, Gerassimos J Mantzaris, Elias A Kouroumalis.   

Abstract

BACKGROUND: Antiglycan antibodies have recently been reported to be associated with Crohn's disease (CD). These antibodies include anti-Saccharomyces cerevisiae mannan antibodies (ASCA), anti-laminariobioside carbohydrate antibodies (ALCA), anti-chitobioside carbohydrate antibodies (ACCA), and anti-mannobioside carbohydrate antibodies (AMCA). AIMS: The aim of this study was to evaluate their diagnostic accuracy in Greek patients with inflammatory bowel disease (IBD).
METHODS: Serum was collected from 191 patients with IBD (85 with ulcerative colitis (UC) and 106 with CD), 29 cases with other causes of intestinal inflammation and 96 healthy controls. Antiglycan antibodies were measured using commercially available enzyme immunoassays.
RESULTS: Higher levels of antiglycan antibodies were detected in patients with CD compared to patients with UC and controls. Although all types of antiglycan antibodies had a high specificity for diagnosing CD, their sensitivity was rather low, with best results obtained with ASCA and ALCA (41.5 and 52.8%, respectively). Increased levels of ASCA and ALCA were associated with stricturing and penetrating disease phenotype, and the need for surgery (p < 0.05).
CONCLUSIONS: Antiglycan antibodies in Greek IBD patients are significantly associated with CD, and especially to phenotypes of complicated disease, with ASCA and ALCA exhibiting the highest sensitivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632100     DOI: 10.1007/s10620-010-1328-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  The value of serologic markers in indeterminate colitis: a prospective follow-up study.

Authors:  Sofie Joossens; Walter Reinisch; Séverine Vermeire; Boualem Sendid; Daniel Poulain; Marc Peeters; Karel Geboes; Xavier Bossuyt; Peggy Vandewalle; Georg Oberhuber; Harald Vogelsang; Paul Rutgeerts; Jean-Frédéric Colombel
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.

Authors:  W J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; B Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; A R Zinsmeister; S R Targan
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

5.  Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease.

Authors:  Marie Joossens; Kristel Van Steen; Julien Branche; Boualem Sendid; Paul Rutgeerts; Francis Vasseur; Daniel Poulain; Franck Broly; Jean-Frédéric Colombel; Séverine Vermeire; Mathias Chamaillard
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

6.  Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.

Authors:  Iris Dotan; Sigal Fishman; Yaara Dgani; Mikael Schwartz; Amir Karban; Aaron Lerner; Oori Weishauss; Larissa Spector; Avi Shtevi; Rom T Altstock; Nir Dotan; Zamir Halpern
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

7.  Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Authors:  Marla C Dubinsky; Ying-Chao Lin; Debra Dutridge; Yoana Picornell; Carol J Landers; Sharmayne Farrior; Iwona Wrobel; Antonio Quiros; Eric A Vasiliauskas; Bruce Grill; David Israel; Ron Bahar; Dennis Christie; Ghassan Wahbeh; Gary Silber; Saied Dallazadeh; Praful Shah; Danny Thomas; Drew Kelts; Robert M Hershberg; Charles O Elson; Stephan R Targan; Kent D Taylor; Jerome I Rotter; Huiying Yang
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

8.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Authors:  Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

9.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

Authors:  William S Mow; Eric A Vasiliauskas; Ying-Chao Lin; Phillip R Fleshner; Konstantinos A Papadakis; Kent D Taylor; Carol J Landers; Maria T Abreu-Martin; Jerome I Rotter; Huiying Yang; Stephan R Targan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease.

Authors:  Daniele Simondi; Giulio Mengozzi; Silvia Betteto; Renato Bonardi; Roberta Patrizia Ghignone; Sharmila Fagoonee; Rinaldo Pellicano; Carlo Sguazzini; Roberto Pagni; Mario Rizzetto; Marco Astegiano
Journal:  Inflamm Bowel Dis       Date:  2008-05       Impact factor: 5.325

View more
  3 in total

Review 1.  Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.

Authors:  Amit Kaul; Susan Hutfless; Ling Liu; Theodore M Bayless; Michael R Marohn; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

2.  Serum anti-glycan antibodies in paediatric-onset Crohn's disease: association with disease phenotype and diagnostic accuracy.

Authors:  Małgorzata Sładek; Agata Wasilewska; Agnieszka Swiat; Adam Cmiel
Journal:  Prz Gastroenterol       Date:  2014-09-16

3.  Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins.

Authors:  Sharad Purohit; Tiehai Li; Wanyi Guan; Xuezheng Song; Jing Song; Yanna Tian; Lei Li; Ashok Sharma; Boying Dun; David Mysona; Sharad Ghamande; Bunja Rungruang; Richard D Cummings; Peng George Wang; Jin-Xiong She
Journal:  Nat Commun       Date:  2018-01-17       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.